Espranor oral lyophilisate is a freeze-dried wafer which dissolves rapidly on the tongue. Espranor is used in adults and adolescent over 15 years of age, as part of a medical, social and psychological treatment programme for addiction. Espranor contains buprenorphine, an opioid (narcotic) analgesic.

2021年3月12日 · Espranor 8 mg used for adults and adolescents over the age of 15, as part of a medical, social, and psychological treatment program for addiction. Espranor 2mg contains buprenorphine, which is a painkiller opioid (a narcotic).

2023年1月18日 · Buprenorphine is used to help you come off street drugs such as heroin. It can prevent or reduce the unpleasant withdrawal symptoms when you stop using such drugs. It is a medicine that is similar to heroin and works as a replacement treatment.

2017年5月8日 · Espranor® oral lyophilisate is a new rapid-dispersing formulation of buprenorphine that is indicated for the substitution treatment of opioid dependence. The effectiveness and tolerability of buprenorphine in this indication is well established.

Espranor oral lyophilisate is a freeze-dried wafer which dissolves rapidly on the tongue. Espranor is used in adults and adolescent over 15 years of age, as part of a medical, social and psychological treatment programme for addiction. Espranor contains buprenorphine, an opioid (narcotic) analgesic. When it is used for the

Indications: Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with Esprano. oral lyophilisate is intended for use in adults and ado. escents aged 15 years or over who have agreed to be treated for addiction. Dosage and administration: Administration i.

2025年2月12日 · Espranor oral lyophilisate is recommended only for the treatment of opioid drug dependence. It is also recommended that the treatment is prescribed by a physician who ensures comprehensive management of the drug addicted patient(s).

The recommended starting dose is 2 mg of Espranor (1 Espranor 2 mg oral lyophilisate). An additional one to two Espranor 2 mg oral lyophilisates may be administered on day one depending on the individual patient’s requirement.

2022年9月14日 · Health Products Regulatory Authority 14 September 2022 CRN00CHRM Page 1 of 11 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Espranor 2 mg Oral Lyophilisate 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each oral lyophilisate contains 2 mg of buprenorphine (as hydrochloride).

Espranor is formulated to provide buprenorphine via a lyophilisate (i.e. a freeze-dried wafer) that dissolves rapidly on the tongue [20], and that may offer advantages over sublingual formulations of buprenorphine. Elements of the proprietary technology used in Espranor enhance the oromucosal absorption of the active pharmaceutical